Abstract
Purpose: Investigating diversity of participants in colorectal cancer clinical trials.
Methods: We conducted a systematic review and meta-analysis of clinical trials on CRC to assess trial representation. Relevant CRC articles were obtained using MEDLINE and Embase. Included studies had to meet the following criteria: evaluated the effect of an intervention for CRC, performed in the U.S., published or posted between January 1, 2018 – December 31, 2023, and written in English. Data, extracted in blinded/duplicate fashion, included information about age, race, sex, and ethnicity. A Participation-to-Disease Representation Ratio (PDRR) was generated from the data, allowing us to quantitatively assess the representation of subjects along with the prevalence of colorectal cancer. Outputs were assigned a score of ‘poor’, ‘fair’, or ‘good’ to denote the subgroup representation within each included CRC clinical trial.
Results: A total of 25 clinical trials met the inclusion criteria. Regarding race and ethnicity representation, 21 studies received a ‘poor’ rating, 4 received a ‘fair’ rating, and none received a ‘good’ rating. For sex representation, 9 studies received a ‘good’ rating, 7 received a ‘poor’ rating, and the remaining did not report sex.
Conclusion: CRC clinical trials in the U.S. predominantly overrepresented white populations while underrepresenting Asian, Black, and Hispanic populations. These findings highlight the need for more equitable representation in clinical trials to ensure that diverse populations benefit from medical research advancements.
Methods: We conducted a systematic review and meta-analysis of clinical trials on CRC to assess trial representation. Relevant CRC articles were obtained using MEDLINE and Embase. Included studies had to meet the following criteria: evaluated the effect of an intervention for CRC, performed in the U.S., published or posted between January 1, 2018 – December 31, 2023, and written in English. Data, extracted in blinded/duplicate fashion, included information about age, race, sex, and ethnicity. A Participation-to-Disease Representation Ratio (PDRR) was generated from the data, allowing us to quantitatively assess the representation of subjects along with the prevalence of colorectal cancer. Outputs were assigned a score of ‘poor’, ‘fair’, or ‘good’ to denote the subgroup representation within each included CRC clinical trial.
Results: A total of 25 clinical trials met the inclusion criteria. Regarding race and ethnicity representation, 21 studies received a ‘poor’ rating, 4 received a ‘fair’ rating, and none received a ‘good’ rating. For sex representation, 9 studies received a ‘good’ rating, 7 received a ‘poor’ rating, and the remaining did not report sex.
Conclusion: CRC clinical trials in the U.S. predominantly overrepresented white populations while underrepresenting Asian, Black, and Hispanic populations. These findings highlight the need for more equitable representation in clinical trials to ensure that diverse populations benefit from medical research advancements.
Original language | American English |
---|---|
Pages | 34 |
State | Published - 13 Sep 2024 |
Event | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health - Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation, Tahlequah, United States Duration: 13 Sep 2024 → 13 Sep 2024 |
Conference
Conference | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health |
---|---|
Abbreviated title | STRIDE 2024 |
Country/Territory | United States |
City | Tahlequah |
Period | 13/09/24 → 13/09/24 |